Trice Medical closed a US $18.3MM Series C Extension financing round. Proceeds will support worldwide commercialization of mi-eye 2™ and mi-ultra™, as well as product development. The company plans to enter large multinational partnerships, per leadership comments.
mi-ultra is a high-powered 15mHz handheld ultrasound transducer optimized for musculoskeletal applications, for use at the first point of care. mi-eye 2 is a handheld, single-use tool comprising a wide-angle camera lens embedded in a disposable needle. Physicians can complete a diagnosis on the spot in a clinic, under local anesthetic.
The funding round was led by Charter Capital Partners and the Municipal Employees’ Retirement System of Michigan. Other investors in Trice include Smith & Nephew, Safeguard Scientifics, HealthQuest Capital and BioStar Ventures.
Trice Medical closed a US $18.3MM Series C Extension financing round. Proceeds will support worldwide commercialization of mi-eye 2™ and mi-ultra™, as well as product development. The company plans to enter large multinational partnerships, per leadership comments.
mi-ultra is a high-powered 15mHz handheld ultrasound transducer optimized for...
Trice Medical closed a US $18.3MM Series C Extension financing round. Proceeds will support worldwide commercialization of mi-eye 2™ and mi-ultra™, as well as product development. The company plans to enter large multinational partnerships, per leadership comments.
mi-ultra is a high-powered 15mHz handheld ultrasound transducer optimized for musculoskeletal applications, for use at the first point of care. mi-eye 2 is a handheld, single-use tool comprising a wide-angle camera lens embedded in a disposable needle. Physicians can complete a diagnosis on the spot in a clinic, under local anesthetic.
The funding round was led by Charter Capital Partners and the Municipal Employees’ Retirement System of Michigan. Other investors in Trice include Smith & Nephew, Safeguard Scientifics, HealthQuest Capital and BioStar Ventures.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
